Table 7 Ranges of estimates of costs averted by STI programs: sensitivity analyses
Cost estimated | Upper and lower bounds obtained in simulations (10th and 90th percentiles) |
|---|---|
Sequelae costs averted by treatment of people with chlamydia and gonorrhea | Base case - 54%, Base case + 60% |
Sequelae costs averted by treatment of people with syphilis | Base case - 28%, Base case + 28% |
Congenital syphilis treatment costs averted | Base case - 36%, Base case + 39% |
Treatment and sequelae costs averted by reducing STIs in the population | Base case - 53%, Base case + 58% |
HIV costs averted through treatment of STIs | Base case - 67%, Base case + 80% |
HIV costs averted by HIV counseling and testing | Base case - 54%, Base case + 60% |
Indirect chlamydia and gonorrhea costs averted | Base case - 35%, Base case + 38% |
Indirect syphilis costs averted | Base case - 35%, Base case + 38% |
Indirect congenital syphilis costs averted | Base case - 36%, Base case + 39% |
Indirect HIV costs averted through treatment of STIs | Base case - 67%, Base case + 80% |
Indirect HIV costs averted by HIV counseling and testing | Base case - 54%, Base case + 60% |